



**HAL**  
open science

## Encrusted Urinary Tract Infections Due to Corynebacteria Species

Hamza Sakhi, Olivier Join-Lambert, Anna Goujon, Thibault Culty, Paul Loubet, Julien Dang, Sylvain Drouot, Hubert de Bayser, Christophe Michaud, Louise Ghislain, et al.

► **To cite this version:**

Hamza Sakhi, Olivier Join-Lambert, Anna Goujon, Thibault Culty, Paul Loubet, et al.. Encrusted Urinary Tract Infections Due to Corynebacteria Species. *Kidney International Reports*, 2021, 6, pp.179 - 186. 10.1016/j.ekir.2020.10.034 . hal-03493113

**HAL Id: hal-03493113**

**<https://hal.science/hal-03493113>**

Submitted on 2 Jan 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 **Encrusted urinary tract infections due to *Corynebacteria* species.**

2

3 Hamza Sakhi<sup>1</sup>, MD, Olivier Join-Lambert<sup>2</sup>, MD, PhD, Anna Goujon<sup>3</sup>, MD, Thibault Culty<sup>3</sup>, MD,  
4 PhD, Paul Loubet<sup>4</sup>, MD, PhD, Julien Dang<sup>5</sup>, MD, Sylvain Drouot<sup>6</sup>, PharmD, Hubert de Bayser<sup>7</sup>,  
5 MD, Christophe Michaud<sup>7</sup>, MD, PhD Louise Ghislain<sup>8</sup>, MD, Thomas Stehlé<sup>9</sup>, MD, Christophe  
6 Legendre<sup>1</sup>, MD Dominique Joly<sup>1</sup>, MD, PhD, Paul Meria<sup>10</sup>, MD, PhD, Mohamad Zaidan<sup>5,11</sup>, MD,  
7 PhD.

8

9 <sup>1</sup> Department of Nephrology-Transplantation, Hôpital Necker, APHP, Paris, France

10 <sup>2</sup> Department of Microbiology, Hôpital Necker, APHP, Paris, France

11 <sup>3</sup> Department of Urology, CHU Angers, Angers, France

12 <sup>4</sup> Department of Infectiology, CHU Nîmes, Nîmes, France

13 <sup>5</sup> Department of Nephrology-Transplantation, Hôpital Bicêtre, APHP, Le Kremlin-Bicêtre,  
14 France

15 <sup>6</sup> Clinical Pharmacy Department, Hôpital Bicêtre, APHP, Paris, France

16 <sup>7</sup> Department of Urology, Hôpital Edouard Herriot, HCL, Lyon, France

17 <sup>8</sup> Department of Nephrology and Dialysis, Hôpital Tenon, APHP, Paris, France

18 <sup>9</sup> Department of Nephrology-Transplantation, Hôpital Henri-Mondor, APHP, Créteil, France

19 <sup>10</sup> Department of Urology, Hôpital Saint-Louis, APHP, Paris, France

20 <sup>11</sup> Paris-Saclay, Le Kremlin-Bicêtre, France

21

22 **Corresponding author:** Dr Hamza Sakhi and Dr Mohamad Zaidan, Department of  
23 Nephrology-Transplantation, Hôpital Necker, APHP, 149 Rue de Sèvres, 75015, Paris, France,  
24 E-mail: sakhi.hamza@gmail.com and mohamad.zaidan@aphp.fr; Phone: +33 650221558

25

26 **Word count: 249 + 2382**

1 **ABSTRACT**

2 **Introduction**

3 Encrusted pyelitis and cystitis are peculiar disorders characterized by the calcification of the  
4 vesical, the pyelic and/or the ureteral walls. These calcifications are composed of struvite  
5 and calcium carbonate-apatite due to the presence of *Corynebacterium urealyticum*.

6 **Methods**

7 We reported the clinical features and outcomes of 17 patients with encrusted pyelitis (n=15)  
8 or encrusted cystitis (n=2). Diagnosis was based on CT scan and sonography including  
9 thickening and calcified lesions of the urinary tract.

10 **Results**

11 Main clinical presentation was suggestive of sub-acute urinary tract infection with fever and  
12 urological symptoms, mostly gross hematuria. Biological features were characterized by the  
13 presence of struvite crystals and alkaline urine. Acute kidney injury (AKI) was reported in  
14 70.6% of cases. Predisposing factors were mostly due to urological background (82.4%) with  
15 a history of urological procedure (71%) and prior exposure to antibiotics (59%). All patients  
16 received appropriate antibiotherapy and 15 were treated with topical urinary acidification. A  
17 significant reduction of encrusted calcifications was observed in 88% of cases. Renal function  
18 improved in 71% of patients. Nevertheless, poor tolerance of the treatment and side effects  
19 were common, affecting 71% of patients with gram-negative bacilli urinary tract infections  
20 (53%) being the most frequent. At last follow-up, 4 patients (23.5%) progressed to end-stage  
21 renal disease and only one had a clinical relapse.

22 **Conclusion**

23 Encrusted urinary tract infections are rare, characterized by a severe renal and overall  
24 prognosis in the absence of appropriate treatment. Topical urinary acidification and  
25 appropriate antibiotherapy are efficient but may be burdened by significant adverse events.

26

27 **Key Words** : Corynebacterium ; Corynebacterium urealyticum ; encrusted cystitis ; encrusted  
28 pyelitis ; encrusted urinary tract infections

29

30

## 31 INTRODUCTION

32 Encrusted urinary tract infections are rare disorders characterized by the calcification  
33 of the bladder (cystitis), the ureteral, and/or the pyelic (pyelitis) walls.<sup>1</sup> Similarly to  
34 infectious-related nephrolithiasis, these calcifications are usually composed of struvite  
35 (ammonium magnesium phosphate) and calcium carbonate-apatite crystals.<sup>2-4</sup> Struvite  
36 stones represent about 10% of nephrolithiasis, and are due to urinary infections with urea-  
37 splitting bacteria.<sup>5</sup> The expression of urease activity allows the conversion of urea and water  
38 into ammonium and bicarbonate leading to urine alkalization (urinary pH is > 7.2).  
39 Subsequent co-precipitation of ammonium with magnesium and phosphate then results in  
40 struvite crystals and urinary encrustations.<sup>6</sup> Urea-splitting agents include a wide range of  
41 pathogens depending on the level of urease activity.<sup>7</sup> Struvite stones are most often related  
42 to upper urinary tract infections due to *Klebsiella sp* and *Proteus sp*. Encrusted pyelitis and  
43 cystitis are almost invariably due to infections by *Corynebacterium urealyticum*, a gram  
44 positive slow-growing bacillus, characterized by a major urease activity that colonizes the  
45 skin.<sup>8,9</sup> *C.urealyticum* is identified in up to 30% of hospitalized patients,<sup>10</sup> and infection  
46 usually develops in a nosocomial context, particularly after exposure to antibiotics.<sup>11</sup>  
47 Encrusted pyelitis and cystitis were initially reported in renal transplant patients.<sup>12</sup> However,  
48 cases involving native kidneys were also reported.<sup>13,14</sup> In the present retrospective study, we  
49 addressed the spectrum and outcome of patients with encrusted urinary tract infections,  
50 focusing more specifically on management and renal outcome.

51

## 52 METHODS

### 53 Study population

54 Patients were retrospectively identified through a French nationwide survey. The diagnosis  
55 of encrusted cystitis and pyelitis was based on imaging features including thickening and  
56 calcified lesions of the bladder and/or renal calyces and pelvis. Diagnosis of isolated  
57 encrusted cystitis was made by ultrasonography while diagnosis of encrusted pyelitis with or  
58 without cystitis was based on CT-scan. The identification of Corynebacteria in the urine was  
59 a major diagnostic criterion. The presence of gram positive bacilli, struvite crystals and/or  
60 alkaline urinary pH ( $\geq 8$ ) was considered as an alternative criterion in the absence of  
61 Corynebacteria.<sup>3</sup>

## 62 **Data Collection**

63 Demographic, clinical and biological data were recorded retrospectively at diagnosis, during  
64 and at the end of follow-up for all patients. Systemic symptoms, signs of cystitis or  
65 pyelonephritis, serum creatinine level, urine culture, urine pH, and crystalluria were  
66 collected. AKI was defined according to clinical practice guidelines.<sup>15</sup> Estimated glomerular  
67 filtration rate (eGFR) was estimated using the simplified Modification of Diet in Renal  
68 Disease equation, and chronic kidney disease (CKD) was defined according to the Kidney  
69 Disease Outcomes Quality Initiative classification.<sup>16</sup> Patients were evaluated by  
70 ultrasonography and/or CT-scan at diagnosis and during follow-up.

## 71 **Treatment modalities and outcome**

72 Treatment modalities included surgical resection of encrusted calcifications, use of topical  
73 urine acidification, and nature of the antibiotics at diagnosis and in case of relapse.  
74 Treatment efficacy was based on clinical assessment, kidney function improvement, imaging  
75 studies, and urine culture. The regression of the calcifications was evaluated by CT-scan  
76 (encrusted pyelitis) and/or ultrasonography (encrusted cystitis) performed at different time  
77 points during follow-up.

## 78 **Statistical analysis**

79 Descriptive statistics were used to summarize the data using STATA 11.2 software  
80 (StataCorp). Continuous variables were expressed using median values with interquartile  
81 range, as appropriate for non-parametric data. Categorical variables were expressed as  
82 counts and percentages for categorical variables.

83

## 84 **RESULTS**

### 85 **Demographic characteristics**

86 Over the last two decades, 17 patients with encrusted pyelitis and/or cystitis, including 7  
87 males and 10 females, were identified from seven different French Hospitals. Two patients  
88 had isolated encrusted cystitis based on ultrasonography findings, and 15 displayed  
89 encrusted pyelitis, associated with encrusted cystitis in three, as assessed by CT-scan. Four  
90 patients had bilateral encrusted pyelitis, and four had encrusted pyelitis on the renal  
91 allograft (**Table 1** and **Figure 1**).

92 Past medical history included type 2 diabetes mellitus (23.5%), untreated HIV infection (one  
93 patient), and autoimmune hepatitis in 4 (one patient). Ten (58.9%) patients had preexisting  
94 CKD with a median eGFR at baseline of 39 [30.5-71.5] ml/min/1.73m<sup>2</sup> (**Table 2** and  
95 **Supplementary Table S1**), but none had been previously referred to a Nephrologist. Four  
96 patients had undergone a renal transplantation. Overall, 14 patients (82.4%) had a  
97 “urological background”, including urological cancer (n=4), former neurogenic bladder (n=3),  
98 urological complication after renal transplantation (n=2) which were lymphocele and  
99 ureteral anastomosis necrosis, extrinsic chronic ureteral obstruction (n=2), and other causes  
100 (n=3). Interestingly, 12 patients (70.6 %) had undergone some kind of urological procedure,  
101 including continent skin diversion or cutaneous ureterostomy in five patients, endoscopic

102 procedures in three cases, and post-transplantation re-intervention in two renal transplant  
103 patients. Two patients had non urological cancer with non-Hodgkin B-cell lymphoma and  
104 colonic cancer with peritoneal carcinomatosis. Finally, 10 patients (59%) had been exposed  
105 to antibiotics prior to diagnosis, most often (n=9) due to urinary tract infections with gram-  
106 negative bacilli (**Table 2** and **Supplementary table S1**).

## 107 **Diagnosis**

108 Presenting features are summarized in **Table 1** and detailed in **Supplementary Table S1**. The  
109 delay between initial symptoms and diagnosis was variable with a median of 2 months  
110 IQR[1-6]. Median age at diagnosis was 67.5 years IQR[56-68]. Eleven patients (64.7%) had  
111 systemic manifestations including weight loss and fever. Urological signs were reported in  
112 more than 70% of cases, including dysuria in two patients with encrusted cystitis. Flank pain  
113 was observed in three cases (20%). Hematuria was present in all but one patient, with gross  
114 hematuria in 64.7% of cases. Inflammatory syndrome was reported in 10 patients, all with  
115 encrusted pyelitis. *Corynebacterium* was identified in 14 patients, but initially missed in 4  
116 cases. *C. urealyticum* was involved in 13 cases and *C. striatum* in one patient. Three patients  
117 had a negative urine culture on standard media, albeit gram positive bacilli were initially  
118 detected on direct urine examination. Alkali urinary pH  $\geq 8$  was a constant finding.  
119 Crystalluria showed struvite crystals in all cases. Acute kidney injury was observed in 12  
120 (70.6%) patients, all with encrusted pyelitis, and dilatation of the collecting duct system was  
121 observed in 11 patients (64.7%). At diagnosis, median serum creatinine was 315  $\mu\text{mol/L}$   
122 IQR[209.8-395].

## 123 **Treatment and outcome**



124 All patients were treated with appropriate antibiotherapy for a median period of 9 weeks  
125 IQR[4.5-12.5]. Intra-venous glycopeptides (Vancomycin or Teicoplanin) were administered in  
126 15 patients, and Linezolid in one.

127 Conservative therapy consisted in topical urine acidification using Thomas' solution (27 g  
128 each of sodium gluconate, citric acid and malic acid, in 1 L of distilled water) or Suby's  
129 solution (citric acid 32.3 g, sodium carbonate 4.4 g, magnesium oxide 3.8 g, distilled water  
130 1 L). Recommended parameters of irrigation were a flow rate of 10-20 ml/h increasing to 50-  
131 100 ml/h with an intrarenal or pelvic pressure < 25 cmH<sub>2</sub>O, but treatment was tailored under  
132 patient's doctor supervision. Treatment was administered through a percutaneous  
133 nephrostomy placed at the initiation of the treatment. All the patients, except two, received  
134 topical acidification, which was administered for a median time of 3 weeks IQR[2-6]. When  
135 available, urine pH acidification (urinary pH < 4) was obtained in all treated patients.  
136 Acetohydroxamic acid was given for one month after topical acidification in two patients,  
137 but was well-tolerated in only one case (**Supplementary Table S2**). Among the two patients  
138 who did not receive acidification therapy, one underwent a surgical resection of the  
139 encrusted material and the other was given Linezolid for only two weeks. The availability of  
140 the topical acidification at the time of management in these two cases was unknown.  
141 Another patient with encrusted pyelitis and struvite stones also underwent a pyelotomy to  
142 extract the stones (**Supplementary Table S2**).

143 All the patients had a favorable clinical and biological response, including the two patients  
144 with isolated encrusted cystitis (**Supplementary table S3**). Nevertheless, poor clinical  
145 tolerance of the topical acidification was reported in four (23.5%) patients due to pain and  
146 malnutrition. Metabolic acidosis was observed in five (29.4%) patients (**Table 3**), whereas  
147 infections were observed in 11 (73.3%) patients. Nine patients developed urinary tract

148 infection with a septic shock in two, one had a cutaneous fistula near the nephrostomy, and  
149 seven displayed urinary candidosis in the course of topical acidification.

150 Urine cultures finally returned negative for *Corynebacteria* in all cases. Complete or partial  
151 regression of encrusted calcifications was observed in 15 patients, including 14 who were  
152 treated by acidification (**Figure 2**). Persistent calcifications were described in 10 (67%)  
153 patients treated by acidification. The non-responder patient was actually treated for only  
154 five days, and before kidney function worsened, leading to treatment discontinuation (**Table**  
155 **3**). At the end of the treatment, renal function improved in almost all cases, whereas it  
156 remains stable in 5 patients, 3 with initially normal baseline value, and 2 with CKD.  
157 Nevertheless, return to baseline value was observed in only 6 patients (35.3%), and median  
158 serum creatinine was 165  $\mu\text{mol/L}$  IQR[105-210] (**Table 3**).

159 Only one of the treated patients with acidification presented a new symptomatic flare. The  
160 patient had been treated less than one week and rapidly progressed to end-stage renal  
161 disease requiring hemodialysis. He finally died from a septic shock. One patient presented a  
162 progression of the encrustations one month after treatment discontinuation, and finally  
163 underwent a surgical resection. Two patients had recurrence of struvite crystals in the urine,  
164 including one with a positive urine culture for *C. urealyticum*, but none displayed *de novo*  
165 renal calcifications or symptomatic encrusted pyelitis. Finally, two patients presented new  
166 struvite stones one of which resulted in obstructive AKI (**Table 3**).

167 At last follow-up, and after a median follow-up time of 15 [10-30] months, median eGFR was  
168 34 mL/min/1.73m<sup>2</sup> IQR[16-70], eight (47%) patients had severe CKD, and four (23.5%) had  
169 reached end-stage renal disease. Four patients died (23.5%) because of urothelial carcinoma  
170 (n=1), progressive lymphoma (n=1), septic shock (n=2) (**Table 3** and **Supplementary table S4**).

171

172

173

174 **DISCUSSION**

175           The present study illustrates the diagnostic challenge, management modalities, and  
176 renal outcome of patients with encrusted pyelitis and/or cystitis. So far, only a few series  
177 have characterized the spectrum of encrusted urinary tract infections due to *Corynebacteria*  
178 species (**Supplementary table S5**).<sup>11–14,17–26</sup>

179 Despite suggestive imaging features, the diagnosis of encrusted urinary tract infections is  
180 challenging given the need for specific culture media to identify *Corynebacteria* species and  
181 the important delay between first symptoms and established diagnosis.<sup>27</sup> Of note, most  
182 patients present with obstructive renal failure, and most have preexisting chronic kidney  
183 disease at the time of diagnosis, suggesting a chronic unrecognized process. Although  
184 urinary tract obstruction is likely the main cause of chronic kidney disease, local  
185 inflammation due to encrustations, and pyelonephritis may also contribute to renal function  
186 deterioration. Recent studies indicate an increase in the incidence of *Corynebacterium*  
187 urinary infections,<sup>25</sup> suggesting a potential underestimation of encrusted pyelitis and cystitis.  
188 *Corynebacterium* urinary colonization is observed in less than 1% of patients, mostly in those  
189 who had been hospitalized and had previous antibiotic treatment and urological gestures, as  
190 observed in our study.<sup>28</sup> At-risk patients include immunocompromised subjects,<sup>12,18</sup> and  
191 those with a heavy urological background, including malignancy and other urological  
192 disorders.

193 Urological gestures associated with a mucosal breach, particularly transurethral prostate  
194 interventions or percutaneous stone surgery, may favor bacterial inoculation within the

195 urinary tract leading to infection in 1-5% of cases.<sup>29</sup> Thus, *Corynebacterium*, which usually  
196 colonizes the skin,<sup>10</sup> may be inoculated within the urinary tract during such procedures.

197 Given the risk of incomplete recovery of renal function after urine diversion and septic shock  
198 with pyelocaliceal microabscesses,<sup>19</sup> an earlier diagnosis would improve renal and overall  
199 outcome. The detection of alkali urine (especially pH  $\geq$  8), and struvite crystals in at-risk  
200 patients may thus be helpful and cost-effective to make an early diagnosis of *Corynebacteria*  
201 infections. CT-scan may also show typical encrusted calcifications. Differential diagnosis  
202 includes other infectious diseases such as schistosomiasis and tuberculosis, cytotoxic  
203 chemotherapy, and underlying neoplastic lesions. Nevertheless, it should be stressed that  
204 the presence of linear calcifications along the pyelic wall is strongly evocative<sup>22</sup>, and the  
205 presence of *Corynebacteria* in urine culture make the diagnosis. However because  
206 *Corynebacteria* are slow-growing germs, and the gram positive rods initially identified on  
207 direct examination may be missed by standard urine culture, the diagnosis should not be  
208 ruled out on the basis of negative standard cultures, and the bacteriologist should be aware  
209 of the suspicion of *Corynebacterium* infection to adapt the medium culture and the  
210 diagnostic procedure.<sup>30</sup> The broader use of modern techniques, such as MaldiTOF, will  
211 certainly allow a more accurate recognition of such species<sup>30</sup> and should be carried out in  
212 these cases.

213 Although *Corynebacterium* seem to be less virulent than other urinary tract bacteria,<sup>4</sup> the  
214 germs are resistant to most of the commonly used antibiotics for urinary tract infections.<sup>11</sup>  
215 Because ineffective treatment is associated with poor outcome,<sup>12</sup> it should be underscored  
216 that glycopeptides with vancomycin represent the most commonly used antibiotics for the  
217 treatment of *Corynebacteria*. Given the risk of nephrotoxicity associated with glycopetids,

218 particularly when prescribed for a prolonged period, the use of linezolid, as reported in one  
219 of our patients, may represent an interesting alternative, but require further investigations.  
220 The present series also illustrates the different options to treat encrusted urinary tract  
221 infections due to *Corynebacteria* species. The management was historically based on the  
222 surgical resection of the encrusted material, which is burdened by a significant risk of  
223 hemorrhage.<sup>1,12,13</sup> Oral acetohydroxamic acid was also proposed as a complementary  
224 treatment, albeit its use was limited because of a poor tolerance<sup>31</sup> and important delay  
225 before significant improvement.<sup>1</sup> As suggested by our study, the combination of topical  
226 urine acidification and antibiotherapy represent a good alternative to control the infection  
227 and improve immediate renal function.

228 Nevertheless, a prolonged hospitalization is most often necessary, exposing to iatrogenic  
229 complications in elderly and frail patients. Acidification may be poorly tolerated and may  
230 require reducing the flow rate of instillation. Patients are also exposed to a high risk of *de*  
231 *novo* urinary tract infections and candiduria, which may convert into septic shock.

232 Altogether, such adverse events may prompt the interruption of the treatment before the  
233 initially defined duration of 4 weeks. Surprisingly, the rate of recurrence seems to be very  
234 low, despite the potential persistence of calcifications in some cases. Indeed, complete  
235 regression of encrustations was observed in only 7 (41.2%) patients. The eradication of  
236 calcifications at any cost should thus be discussed in the light of treatment tolerance and  
237 overall prognosis.

238

239 In conclusion, encrusted pyelitis and cystitis affect frail patients with a long-standing  
240 urological history and comorbid conditions. Early diagnosis is mandatory to initiate  
241 appropriate treatment. The therapeutic strategy is unique compared to other urinary tract

242 infections. The combination of topical urine acidification and antibiotherapy represents an  
243 alternative to surgery. Nevertheless, treatment tolerance and potential complications should  
244 also be considered. Further studies would help to better clarify treatment modalities,  
245 including the duration of urine acidification and antibiotherapy. A better monitoring of at-  
246 risk patients would also improve renal and overall outcomes.

247

248

## 249 **FIGURE LEGENDS**

250 **Figure 1. Abdominal CT-scan findings at diagnosis** showing bilateral encrusted pyelitis of  
251 the native kidney (**A and B, red arrows**), the kidney graft (**C, red arrows**), and encrusted  
252 cystitis (**D, red arrows**).

253

254 **Figure 2. Comparison of CT-Scan findings** before (left panels) and after (right panels)  
255 treatment by topical acidification and antibiotics in case of encrusted pyelitis on native (**A**  
256 **and B**) or kidney graft (**C**) showing a significant reduction of encrusted calcifications (red  
257 arrows) at the end of treatment.

258

## 259 **AUTHOR CONTRIBUTIONS**

260 H.S. : Conceptualization, Investigation, Writing- Original draft preparation, O.J-L. :  
261 Resources. A.G. : Resources ; T.C. : Resources ; P.L. : Resources, Writing - Review & Editing ;  
262 J.D. : Resources ; S.D. : Resources ; H.d.B. : Resources; C.M. : Resources ; L.G. : Resources ;  
263 T.S. : Resources, Writing - Review & Editing ; C.L. : Resources D.J. : Resources ;  
264 P.M. : Resources, Supervision, Writing - Review & Editing ; M.Z. : Writing - Review & Editing,  
265 Supervision.

266

267 **ACKNOWLEDGMENTS**

268 We would to thank Dr Eugénie Koumakis for her helpful editing advice.

269

270 **DISCLOSURES**

271 The authors have nothing to disclose

272

273

274

275

276 **REFERENCES**

- 277 1. Meria P, Jungers P. Encrusted pyelitis: an underdiagnosed condition? *Nephrol Dial*  
278 *Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc.* 2000;15(7):943-945.
- 279 2. Nadler RB, Hoffman TA, McClennan BL, Clayman RV. *Corynebacterium urealyticum*  
280 (CDC Group D2) associated with staghorn calculus: treatment by percutaneous debulking  
281 and chemolysis. *J Endourol.* 1996;10(1):31-34. doi:10.1089/end.1996.10.31
- 282 3. Meria P, Desgrippes A, Arfi C, Le Duc A. Encrusted cystitis and pyelitis. *J Urol.*  
283 1998;160(1):3-9.
- 284 4. Soriano F, Ponte C, Santamaría M, Castilla C, Fernández Roblas R. In vitro and in vivo  
285 study of stone formation by *Corynebacterium* group D2 (*Corynebacterium urealyticum*). *J*  
286 *Clin Microbiol.* 1986;23(4):691-694.
- 287 5. Bichler K-H, Eipper E, Naber K, Braun V, Zimmermann R, Lahme S. Urinary infection  
288 stones. *Int J Antimicrob Agents.* 2002;19(6):488-498. doi:10.1016/S0924-8579(02)00088-2
- 289 6. Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stones—pathogenesis,  
290 microbiology and management strategies. *Nat Rev Urol.* 2014;11(6):333-341.  
291 doi:10.1038/nrurol.2014.99
- 292 7. N. Noël and P. Rieu, Lithiase urinaire d'infection. EMC-Urologie;6(2):1-8[Article 18-  
293 104C-10], 2013
- 294 8. Soriano F, Tauch A. Microbiological and clinical features of *Corynebacterium*  
295 *urealyticum*: urinary tract stones and genomics as the Rosetta Stone. *Clin Microbiol Infect.*  
296 2008;14(7):632-643. doi:10.1111/j.1469-0691.2008.02023.x
- 297 9. Tauch A, Trost E, Tilker A, et al. The lifestyle of *Corynebacterium urealyticum* derived



298 from its complete genome sequence established by pyrosequencing. *J Biotechnol.*  
299 2008;136(1-2):11-21. doi:10.1016/j.jbiotec.2008.02.009

300 10. Soriano F, Rodriguez-Tudela JL, Fernández-Roblas R, Aguado JM, Santamaría M. Skin  
301 colonization by *Corynebacterium* groups D2 and JK in hospitalized patients. *J Clin Microbiol.*  
302 1988;26(9):1878-1880.

303 11. López-Medrano F, García-Bravo M, Morales JM, et al. Urinary tract infection due to  
304 *Corynebacterium urealyticum* in kidney transplant recipients: an underdiagnosed etiology  
305 for obstructive uropathy and graft dysfunction-results of a prospective cohort study. *Clin*  
306 *Infect Dis Off Publ Infect Dis Soc Am.* 2008;46(6):825-830. doi:10.1086/528713

307 12. Aguado JM, Morales JM, Salto E, et al. Encrusted pyelitis and cystitis by  
308 *Corynebacterium urealyticum* (CDC group D2): a new and threatening complication following  
309 renal transplant. *Transplantation.* 1993;56(3):617-622.

310 13. Hertig A, Duvic C, Chretien Y, Jungers P, Grünfeld JP, Rieu P. Encrusted pyelitis of  
311 native kidneys. *J Am Soc Nephrol JASN.* 2000;11(6):1138-1140.

312 14. Giannakopoulos S, Alivizatos G, Deliveliotis C, Skolarikos A, Kastriotis J, Sofras F.  
313 Encrusted cystitis and pyelitis. *Eur Urol.* 2001;39(4):446-448. doi:10.1159/000052483

314 15. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group.  
315 KDIGO Clinical Practice Guideline for Acute Kidney Injury. *Kidney inter., Suppl.* 2012; 2 : 1–  
316 138.

317 16. Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical  
318 practice guideline for the evaluation and management of CKD. *Am J Kidney Dis Off J Natl*  
319 *Kidney Found.* 2014;63(5):713-735. doi:10.1053/j.ajkd.2014.01.416

- 320 17. Aguado JM, Ponte C, Soriano F. Bacteriuria with a multiply resistant species of  
321 *Corynebacterium* (*Corynebacterium* group D2): an unnoticed cause of urinary tract infection.  
322 *J Infect Dis.* 1987;156(1):144-150.
- 323 18. Soriano F, Aguado JM, Ponte C, Fernández-Roblas R, Rodríguez-Tudela JL. Urinary  
324 tract infection caused by *Corynebacterium* group D2: report of 82 cases and review. *Rev*  
325 *Infect Dis.* 1990;12(6):1019-1034.
- 326 19. Meria P, Desgrippes A, Fournier R, et al. The conservative management of  
327 *corynebacterium* group D2 encrusted pyelitis. *BJU Int.* 1999;84(3):270-275.
- 328 20. Moreno Arcas P, Anglada Curado FJ, Prieto Castro R, et al. [Encrusted pyelitis.  
329 Lithiasic disease with infectious etiology]. *Actas Urol Esp.* 2002;26(1):53-56.
- 330 21. Audard V, Garrouste-Orgeas M, Misset B, et al. Fatal septic shock caused by  
331 *Corynebacterium* D2. *Intensive Care Med.* 2003;29(8):1376-1379. doi:10.1007/s00134-003-  
332 1865-1
- 333 22. Vázquez V, Morales MD, Serrano C, Reus M, Llorente S, García J. [*Corynebacterium*  
334 *urealyticum* in renal trasplantation. CT and sonography imaging characteristics of encrusted  
335 cystitis and pielitis]. *Nefrol Publicacion Of Soc Espanola Nefrol.* 2004;24(3):288-293.
- 336 23. Khallouk A, Wallerand H, Kleinclauss F, Bittard H, Bernardini S. [Conservative  
337 management of *Corynebacterium urealyticum* encrusted cystitis]. *Progres En Urol J Assoc*  
338 *Francaise Urol Soc Francaise Urol.* 2006;16(4):496-498.
- 339 24. Cappuccino L, Bottino P, Torricella A, Pontremoli R. Nephrolithiasis by  
340 *Corynebacterium urealyticum* infection: literature review and case report. *J Nephrol.*  
341 2014;27(2):117-125. doi:10.1007/s40620-014-0064-1

- 342 25. Sánchez-Martín FM, López-Martínez JM, Kanashiro-Azabache A, et al.  
343 *Corinebacterium urealyticum*: increased incidence of infection and encrusted uropathy.  
344 *Actas Urol Esp.* 2016;40(2):102-107. doi:10.1016/j.acuro.2015.09.007
- 345 26. Saljoghi R, Lipsker A, Caillet K, et al. Encrusted Uretero-pyelitis: Case Report. *Urol*  
346 *Case Rep.* 2016;7:58-60. doi:10.1016/j.eucr.2016.04.014
- 347 27. Sakhi H, Adjaoud D, Hennequin C, et al. The Case | Acute kidney injury, flank pain,  
348 and kidney calcifications in an 80-year-old woman. *Kidney Int.* 2018;93(2):527-528.  
349 doi:10.1016/j.kint.2017.08.017
- 350 28. Nebreda-Mayoral T, Muñoz-Bellido JL, Garcia-Rodríguez JA. Incidence and  
351 characteristics of urinary tract infections caused by *Corynebacterium urealyticum*  
352 (*Corynebacterium* group D2). *Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol.*  
353 1994;13(7):600-604. doi:10.1007/BF01971313
- 354 29. Grabe M, Botto H, Cek M, et al. Preoperative assessment of the patient and risk  
355 factors for infectious complications and tentative classification of surgical field  
356 contamination of urological procedures. *World J Urol.* 2012;30(1):39-50.  
357 doi:10.1007/s00345-011-0722-z
- 358 30. Salem N, Salem L, Saber S, Ismail G, Bluth MH. *Corynebacterium urealyticum*: a  
359 comprehensive review of an understated organism. *Infect Drug Resist.* 2015;8:129-145.  
360 doi:10.2147/IDR.S74795
- 361 31. Griffith DP, Khonsari F, Skurnick JH, James KE. A randomized trial of acetohydroxamic  
362 acid for the treatment and prevention of infection-induced urinary stones in spinal cord  
363 injury patients. *J Urol.* 1988;140(2):318-324.

364

365

366 **Table 1. Patients' characteristics at diagnosis.**

	<b>All Patients (n =17)</b>
<b>Demographic data</b>	
Age, median (IQR)	67.5 (56-68)
Female, n (%)	10 (58.8)
<b>Presenting symptoms</b>	
Delay between 1 <sup>st</sup> symptoms and diagnosis (months), median (IQR)	2 (1-6)
Weight-loss	6 (35.3)
Fever	7 (41.2)
Dysuria	2 (11.8)
Flank or suprapubic pain	4 (23.5)
Gross hematuria	11(64.7)
<b>Biological parameters</b>	
Inflammatory syndrome	10 (58.8)
Renal function	
- SCr ( $\mu\text{mol/L}$ ), median (IQR)	315 (209.8-395)
- Underlying CKD, n (%)	10 (58.9)
- AKI, n (%)	12 (70.6)
- Hydronephrosis, n (%)	11 (64.7)
Urine pH >8, n (%)	11/11 (100)
Struvite crystals, n (%)	11/11 (100)
<b>Radiological findings (CT scan, sonography)</b>	
Isolated cystitis	2
Encrusted pyelitis	15
- Unilateral pyelitis	7 (46.7)
- Bilateral pyelitis	4 (26.7)
- Kidney graft pyelitis	4 (26.7)
- With encrusted cystitis	3 (20)

367

368

369

370

371

372 **Table 2. Patients' past medical history.**

	<b>All Patients (n =17)</b>
<b>General history</b>	
Renal transplantation, n (%)	4(23.5)
Type 2 Diabetes mellitus, n (%)	4 (23.5)
Chronic kidney disease, n (%)	10 (58.9)
- Baseline eGFR (ml/min/1.73m <sup>2</sup> , median (IQR)	39 (30.5-71.5)
HIV/Auto immune hepatitis, n (%)	2 (13.3)
Non urological cancer, n (%)	2(13.3)
<b>Urological history</b>	
Prior urinary tract infection, n (%)	9 (52.9)
Urological disease, n (%)	14 (82.4)
- Urological cancer, n (%)	4 (23.5)
- Post transplantation complications, n (%)	2 (11.8)
- Neurogenic bladder, n (%)	3 (17.6)
- Extrinsic chronic ureteral obstruction, n (%)	2 (11.8)
- Other, n (%)	3 (17,6)
Urological procedures	12 (70.6)
- Continent skin diversion/cutaneous ureterostomy, n (%)	5 (29.4)
- Post-transplantation reintervention, n (%)	2 (11.8)
- Endoscopic procedure without further surgery, n (%)	3 (17.6)
- Other (scrotal fistula surgery/unilateral nephrectomy, n (%)	2 (11.8)

373

374

375

376

377

378

379

380





381

382

383 **Table 3. Patients' outcome at the end of treatment and at last follow-up**






	All Patients (n =17)
<b>At the end of treatment</b>	
<b>Response evaluation</b>	
Negative urine culture for Corynebacteria, n (%)	17 (100)
Urine pH, median (IQR)	6.5 (6.3-6.7)
Renal calcification reduction observed, n (%)	15 (88.2)
Persistent residual calcifications, n (%)	10 (58.8)
<b>Renal function assessment</b>	
Normal renal function, n (%)	3 (17.6)
Improvement of kidney function, n (%)	11 (64.7)
- Return to baseline function, n (%)	6 (35.3)
No improvement, n (%)	1 (5.9)
Stable renal function, n (%)	2 (11.8)
Creatinine, median (IQR)	165 (105-210.5)
<b>Side effects</b>	
Infections	
- Urinary tract infections, n (%)	9 (52.9)
- Candiduria, n (%)	7 (41.2)
Metabolic acidosis, n (%)	5 (29.4)
Poor clinical tolerance (pain, fistula, other), n (%)	4 (23.5)
<b>At last follow-up</b>	
<b>Follow up (months), median, IQR</b>	15 (10 – 30)
<b>Kidney assessment</b>	
eGFR(ml/min/1.73m <sup>2</sup> ), median (IQR)	34 (16-70)
eGFR <30ml/min/1.73m <sup>2</sup> , n (%)	8 (47.1)
ESRD, n (%)	4 (23.5)
<b>Relapse</b>	
Clinical relapse, n (%)	1 (5.9)
Asymptomatic relapse suspected, n (%)	3 (17.6)
- Crystal struvite, n (%)	2 (11.8)
- Positive culture, n (%)	1 (5.9)
- Encrustation progression, n (%)	1 (5.9)
Renal calculi, n (%)	2 (11.8)

384



Before Treatment

After Treatment






# Encrusted urinary tract infections (UTI) due to *Corynebacteria* species

## DIAGNOSIS

### 17 patients with encrusted UTI

Encrusted pyelitis  
n = 15



Isolated  
Encrusted Cystitis  
n=2

#### Past medical history



- urological background
- antibiotics exposure

#### Characteristics

- sub-acute UTI
- gross hematuria
- AKI

#### Urine analysis


- gram (+) rods
- alkaline urine
- struvite crystals



## TREATMENT

Topical  
urine  
acidification

Prolonged  
antibiotherapy  
(glycopeptides)



## OUTCOME

### Encrustations

Reduction  
88%

Relapse  
6%

### Kidney function

Improvement  
65%

ESRD  
24%

### Side effects

UTI  
50%

Metabolic  
acidosis  
29%

### CONCLUSION:

Encrusted urinary tract infections primarily affect patients with heavy urological background.s Topical acidification is an effective treatment.